Goldman Sachs Group Inc. Sells 41,877 Shares of AxoGen, Inc. $AXGN

Goldman Sachs Group Inc. decreased its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 13.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 272,814 shares of the medical equipment provider’s stock after selling 41,877 shares during the quarter. Goldman Sachs Group Inc. owned about 0.60% of AxoGen worth $5,047,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of AXGN. Invesco Ltd. boosted its stake in AxoGen by 2,124.5% during the 1st quarter. Invesco Ltd. now owns 382,429 shares of the medical equipment provider’s stock worth $7,075,000 after acquiring an additional 365,237 shares during the last quarter. Nuveen LLC bought a new position in AxoGen during the 1st quarter worth approximately $5,668,000. Driehaus Capital Management LLC boosted its stake in AxoGen by 22.8% during the 1st quarter. Driehaus Capital Management LLC now owns 1,172,029 shares of the medical equipment provider’s stock worth $21,683,000 after acquiring an additional 217,590 shares during the last quarter. Informed Momentum Co LLC lifted its stake in AxoGen by 558.7% in the first quarter. Informed Momentum Co LLC now owns 240,737 shares of the medical equipment provider’s stock valued at $4,454,000 after buying an additional 204,190 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in AxoGen by 21.1% in the first quarter. Assenagon Asset Management S.A. now owns 1,001,217 shares of the medical equipment provider’s stock valued at $18,523,000 after buying an additional 174,681 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.

AxoGen Stock Performance

Shares of AXGN stock opened at $16.73 on Wednesday. The company’s fifty day simple moving average is $14.32 and its 200-day simple moving average is $14.19. The company has a quick ratio of 2.67, a current ratio of 4.14 and a debt-to-equity ratio of 0.59. The firm has a market cap of $769.75 million, a PE ratio of -167.28 and a beta of 1.03. AxoGen, Inc. has a 12 month low of $9.22 and a 12 month high of $21.00.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $26.00.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.